Clinical Report: Evaluation of Exosome-like Nanoparticles from Nerium oleander

Overview

This study investigates the therapeutic efficacy of exosome-like nanoparticles derived from Nerium oleander (NELNs) against triple-negative breast cancer (TNBC) cells. The findings indicate that NELNs induce significant cytotoxicity and apoptosis in MDA-MB-231 cells.

Background

Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, limiting treatment options. Conventional chemotherapy often leads to significant toxicity and resistance, necessitating the exploration of alternative therapies. Nerium oleander has demonstrated anticancer activity through leaf extracts; however, the role of exosome-like nanoparticles derived from its flowers (NELNs) remains unexplored.

Data Highlights

Key Findings

• NELNs induced significant cytotoxicity in MDA-MB-231 TNBC cells.
• Apoptosis was promoted, with increased intracellular ROS levels observed.
• Flow cytometry confirmed alterations in cell cycle progression.
• Pathway enrichment analysis highlighted arachidonic acid and linoleic acid metabolism.
• Cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP3A4) were identified as putative targets.
• Molecular docking predicted favorable binding interactions of NELN metabolites with these targets.

Clinical Implications

The findings suggest that NELNs may represent a promising alternative treatment for TNBC, potentially addressing the limitations of conventional chemotherapy. Further research is warranted to explore their clinical application and efficacy in vivo.

Conclusion

This study provides preliminary evidence supporting the antiproliferative and pro-apoptotic effects of NELNs against TNBC cells.

Related Resources & Content

1. The ASCO Post, 2024 -- Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer
2. The ASCO Post, 2016 -- Novel Strategies Emerging for Triple-Negative Breast Cancer
3. The ASCO Post, 2014 -- Tackling the Heterogeneity of Triple-Negative Breast Cancer
4. the asco post — Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation
5. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
6. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine
7. Clinical relevance of extracellular vesicles in cancer — therapeutic and diagnostic potential | Nature Reviews Clinical Oncology